Technology digest: non-viral vectors
The advent of gene therapies has offered hope to address previously untreatable genetic disorders, such as protein deficiency disorders or monogenetic deficiencies. Using various techniques to correct or simply replace disease-causing genetic fragments, inherited and acquired diseases have been treated, although currently with varying success. Identifying the most suitable vector to deliver genetic materials in the production of an investigational therapeutic product is key to reducing manufacturing risk, ensuring consistency and reproducibility, and realizing the revolutionary potential of genome engineering.
Included in this download:
- [TECHNOLOGY DIGEST] Non-viral vectors
- [REVIEW] Current reprogramming systems in regenerative medicine: from somatic cells to induced pluripotent stem cells
- [PRIORITY PAPER EVALUATION] Sleeping Beauty transposon system – future trend in T-cell-based gene therapies?
- [REVIEW] Biomaterials and stem cells as drug/gene-delivery vehicles for Parkinson’s treatment: an update
In association with